BANK VONTOBEL/CALL/MEDTRONIC/94/0.1/20.12.24 Stock

Warrant

DE000VD3SVL8

Market Closed - Bid/Ask 01:53:21 2024-07-16 pm EDT Pre-market 02:35:09 am
0.032 EUR +6.67% Intraday chart for BANK VONTOBEL/CALL/MEDTRONIC/94/0.1/20.12.24 0.037 +15.62%
Current month-42.86%
1 month-61.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-16 0.032 +6.67%
24-07-15 0.03 -21.05%
24-07-12 0.038 -9.52%
24-07-11 0.042 +31.25%
24-07-10 0.032 -5.88%

Real-time Boerse Frankfurt Warrants

Last update July 16, 2024 at 01:53 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Vontobel Vontobel
WKN VD3SVL
ISINDE000VD3SVL8
Date issued 2024-04-09
Strike 94 $
Maturity 2024-12-20 (157 Days)
Parity 10 : 1
Emission price 0.22
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.26
Lowest since issue 0.03
Spread 0.01
Spread %23.26%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
78.1 USD
Average target price
93.24 USD
Spread / Average Target
+19.38%
Consensus